← Leaderboards
Graham Beaton
Epigen Biosciences, Inc.
$1,190,053
Attributed
$2,444,409
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2014–22$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,444,409 · 3
By mechanism
R44$2,026,502 · 1
R41$225,000 · 1
U18$192,907 · 1
Top collaborators
- Nigel A Calcutt2 shared
- Victor V Uteshev-Gaard2 shared
- Michael J. Forster1 shared
Most similar at Epigen Biosciences, Inc.
Same institution · by research overlap
- Fabio Cohen Tucci$6,913,476
- Satheesh B Ravula$2,140,663
- Kevin Bacon$149,473
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadRattusBrainNovel TherapeuticsBiochemicalSafetyPhysiologicalFda ApprovedEffective TherapyUniversitiesPreclinical EfficacyBaseDrebrinsAlzheimer&AposDiabetic NeuropathiesAdme StudyDiabetic RatDrug DistributionBrain InjuriesDiabetes MellitusAgonistDensityCaliforniaCytochrome P450
Grant awards (4)
Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy$990,691
R44 · FY2022 · DK · contact PI
Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy$1,035,811
R44 · FY2021 · DK · contact PI
Novel modulators of ÃÂÃÂÃÂñ7 nAChRs as treatments for nicotine reward$192,907
U18 · FY2021 · DA · contact PI
Novel Therapeutic Opportunity in Stroke$225,000
R41 · FY2014 · NS